Abstract: The invention relates to crystal forms A and B of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine hydrochloride (Org 12962), to methods for the preparation of those crystal forms and to pharmaceutical compositions comprising crystal form B.

Abstract: The invention relates to neuroleptic/antidepressant 4-[4- or 6-(trifluoromethyl)-2-pyridinyl]-1-piperazinylalkyl substituted lactam derivatives having the general structure of formula I: ##STR1## wherein one of the groups R.sub.1 and R.sub.2 is CF.sub.3, and the other is hydrogen or CF.sub.3 ;R.sub.3 is hydrogen or (1-4 C) alkyl;n is an integer from 4 to 5; andm is an integer from 1 to 2; or pharmaceutically acceptable salts thereof.The invention also includes processes for making the compounds and their salts.

Abstract: Disclosed are compounds displaying improved preferential serotonin-1A binding activity. The claimed compounds have the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of hydroxy, halogen, lower alkyl, lower alkoxy, and hydrogen;R.sub.2 is hydrogen or lower alkyl;X is CH or a nitrogen atom;ALK is a saturated, branched or unbranched, aliphatic hydrocarbon having from 1 to 7 carbon atoms; andZ is selected from the group consisting of hydrogen, halogen, hydroxy, trifluoromethyl, or lower alkyl;or a pharmaceutically acceptable salt thereof.

Abstract: Pharmaceutical composition which is useful as a medicinal product, in particular for the treatment of disorders of the central nervous system, characterized in that it contains customary pharmaceutical excipients, and at least one of the compounds of formula ##STR1## in which the trifluoromethyl substituent is at the 4-position, at the 5-position, or at 4- and 5-positions of the pyridinyl ring, and the substituent R denotes either hydrogen or a halogen, such as chlorine, at position(s) of the pyridinyl ring not occupied by CF.sub.3, and its pharmaceutically acceptable salts.

Abstract: Compounds of formula: ##STR1## in which R and R' each denote an alkyl or cycloalkyl radical having 1 to 7 carbon atoms; X denotes --O-- or H.sub.2 ; and Y and Z denote hydrogen or one or more radicals chosen from halogeno, hydroxy, straight or branched alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, trifluoromethyl or methylenedioxy; n being able to assume the values 2 or 3; and their pharmaceutically acceptable salts.Application as a cardiovascular medicinal product.

Abstract: Compounds of formula: ##STR1## in which R and R' denote an alkyl radical having 1 to 7 carbon atoms; R.sub.1 denotes hydrogen or an alkyl radical having 1 to 7 carbon atoms; and R.sub.2 and R.sub.3 denote, separately, an alkyl radical having 1 to 7 carbon atoms or a phenyl radical, or, together with the carbon atom to which they are attached, a cycloalkyl radical having at most 7 carbon atoms; n may assume the values 2 or 3; and their pharmaceutically acceptable salts.Application as a cardiovascular medicinal product.

Abstract: The invention relates to compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof, in which X represents either --CH.dbd. or --N.dbd., R.sub.1 represents an alkyl radical having 1 to 5 carbon atoms, R.sub.2 represents hydrogen and R.sub.3 is an alkyl radical having 1 to 5 carbon atoms, or R.sub.2 and R.sub.3, together with the nitrogen atom to which they are bonded, represent a heterocyclic radical, such as pyrrolidinyl, morpholino, 4-phenyl-piperazinyl, in which the phenyl radical can carry one or more substituents, such as a halogen atom, an alkyl or alkoxy radical having 1 to 5 carbon atoms or the trifluoromethyl radical, or represents 4-(2-pyrimidinyl)-piperazinyl, having anti-bronchoconstrictory properties.

Abstract: The invention is dealing with compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof, in which R.sub.1 and R.sub.2 each represent a lower alkyl radical or a phenyl radical, or, together with the carbon atom to which they are bound, a cycloalkyl radical having at the most 7 carbon atoms; R.sub.3 represents hydrogen, a lower alkyl radical, or the phenyl radical; R.sub.4 and R.sub.5 each represent a lower alkyl radical, or, together with the nitrogen atom to which they are bound, a heterocyclic amino radical such as the pyrrolidinyl or morpholino radicals; and R.sub.6 represents a lower alkyl radical, a phenyl radical, a benzyl radical, or the 1-ethynyl-cyclohexyl radical, which compounds can be used in the treatment of angina pectoris.